Gapping down
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- NEOG -3.3%
Other news:
- AKRO -62.7% (reports 36-week analysis of 96-week phase 2b symmetry study with a trend on fibrosis improvement and statistically significant results for nash resolution markers of liver injury and fibrosis insulin sensitization and lipoproteins)
- VTYX -17.5% (positive results from VTX002 Phase 2 trial)
- PD -6.4% ($350 mln convertible senior notes)
- BBIO -4.9% (NEJM publication of positive encaleret proof-of-concept phase 2b results in patients with autosomal dominant hypocalcemia type 1)
- CYRX -3.2% (new partnership with Be The Match BioTherapies)
- EFXT -3.1% (appoints Preet Dhindsa as interim Chief Financial Officer)
- UROY -2.9% (entered into an agreement with a syndicate of underwriters led by BMO Capital Markets as sole bookrunner under which the underwriters have agreed to purchase on a bought deal basis 10205000 common shares at a price of $2.94/share)
- XENE -0.7% (publishes XEN1101 Phase 2b results)
Analyst comments:
- JNPR -3.5% (downgraded to Neutral from Overweight at JP Morgan)
- GLW -2.7% (downgraded to Neutral from Overweight at JP Morgan)
- NTST -2.3% (downgraded to Underperform from Neutral at BofA Securities)
- STWD -1.5% (downgraded to Mkt Perform from Outperform at Keefe Bruyette)
- SRC -1.4% (downgraded to Underperform from Neutral at BofA Securities)
- NEP -1% (downgraded to Neutral from Buy at UBS)